Today we announced that we're saying "Au revoir" - but not goodbye! - to one of our board members, Professor Harriet De Wit. I wanted to share a few thoughts. It's somewhat lost to the mists of time now, but when I was starting the company I convinced @ProfDavidNutt to join us

Press release:

PharmAla is pleased to announce the launch of NEXUS, its new and updated tool to bring together and connect Prescribers, Therapists and Clinic managers.  $mdma

Press release:

PharmAla is pleased to announce that it has completed its shipment of LaNeo™ MDMA to Johns Hopkins University from its newly onboarded distribution site in the United States. $mdma

@bryan_johnson If you want to know more about what MDMA can do in fields as diverse as chronic pain, couples therapy, or fear disorders, let us know - we’re currently involved in about 25 different MDMA clinical trials!

https://t.co/rMiaJAKViF

What have we been working on? Find out in the interview our CEO recently did on Stockhouse’ The Watchlist - link in next tweet!

PharmAla is pleased to announce that it has signed an agreement with Veridion Group to act as its distribution partner in New Zealand. New Zealand recently approved the first authorized psychiatrist allowed to treat patients with Psilocybin, and several applications are underway

Congratulations to our board member, Dr. Harriet de Wit, who delivered the Bryan Kolb lecture at the University of Calgary.

PharmAla is happy to announce that it has completed import operations and release to the United States. PharmAla announced contracting of this new distribution site on March 24, 2025. Press Release: https://t.co/pxjqJyPEP9 $mdma #psychedelics

PharmAla is growing our digital presence. AI is not just impacting how we deal with clients and government - it's impacting how we find new drugs and shape the future of neurological care. Come join us as our Digital and AI lead! https://t.co/LGSdgfRIJ1

PharmAla is hiring! If you're looking for an exciting job in a rapidly growing field - anchored by the best team in the business apply today. View our opportunities here. https://t.co/UUplZtxD0B

Will Avery, PharmAla Biotech CFO, highlights key financial milestones: FY24 revenue up 95% to $1 M+; resumed SAP shipments in Canada & the U.S.; expanded clinical trial deliveries via a new U.S. distributor; and raised $1.5 M+ through Q3 ’25. $mdma #psychedelicnews

PharmAla is pleased to announce that it has incorporated PharmAla Biotech Australia Pty Ltd., a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia. Press release: https://t.co/GwFrw4idOA $mdma #psychedelicnews

One of the things that always bothered me about the ICER decision on MDMA-Assisted Therapy which precipitated the denial of MDMA-AT by the US was the numbers cited. @PharmAlaBiotech treats patients, and we know that the real world costs of treatment are actually very reasonable:

After decades of limited options, the VA is finally investing in psychedelic research, including MDMA-assisted therapy for PTSD. Phase 3 trials show 67% of participants no longer met PTSD criteria. With bipartisan support, this could be a turning point in veteran mental health

Psychedelic therapies have a multitude of benefits serving diverse populations. Access to these treatments is vital not only for our growing mental health crisis but also for our economic productivity as well. #psychedelicscience #ptsd #mdma #mdmatherapy

PharmAla delivers 500+ LaNeo™ 40mg MDMA capsules to Merhavim Mental Health Centre for a PTSD clinical trial. In return for our MDMA, we gain access to the trial’s data & IP — a novel data-for-drug model that could reshape psychedelic research. 👏 👉